Utility of cooling patches to prevent hand-foot syndrome caused by pegylated liposomal doxorubicin in breast cancer patients

Table 8 Factors that may be related to the occurrence of hand-foot syndrome

Possible risk factors	F	Z	P value
Age	3.354		0.387
BMI	0.088		0.581
Body surface area		-0.649	0.517
Race		-0.2	0.842
Profession		-3.023	0.003
Education		-0.597	0.55
Whether the patient has hypertension		-0.887	0.375
Whether the patient has diabetes		-1.008	0.313
Whether the patient ever had heart disease		-1.04	0.298
Whether the patient has other tumors		-0.896	0.37
Whether the patient has a long-term medication history		-2.083	0.037
Whether the patient has a smoking history		-0.512	0.608
Whether the patient has a drinking history		0	1
Whether the patient has the habit of taking health products		-1.04	0.298
Attitude		-0.363	0.717
Character traits		-1.459	0.145
Facing major events in life		-1.229	0.219
Attitude to this matter (suffering from breast cancer)		-1.26	0.208
Whether the patient has undergone surgery		-0.127	0.899
Surgical approach		-1.137	0.255
Chemotherapy administration		-0.182	0.856
Chemotherapy regimen		-1.398	0.162
Total PDL dose		-0.289	0.773
Leukocytes		-0.816	0.415
Platelets		-1.712	0.087
Albumin		-2.428	0.015
Alanine aminotransferase		-1.177	0.239
Aspartate aminotransferase		-1.517	0.129
Total bilirubin		-0.833	0.405
Creatinine		-0.448	0.654
Urea Nitrogen		-0.088	0.93

PLD: Pegylated liposomal doxorubicin; BMI: Body mass index.